TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Binucleated cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Karyorrhexis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Karyolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pycnotic nucleus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nuclear buds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Condensed chromatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of underrepresented minority participants enrolled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: change in gamma-glutamyl transferase (GGT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Number of participants with different pregnant outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Pulmonary vein reconnection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Opioid withdrawal symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Psychophysical Olfactory Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Olfactory-related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Interference screw presence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Serum Responses of ADA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of different types of immune cell populations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Activation of lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of innate lymphoid cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentage of patients without disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite endpoint of death or re-admission due to heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Aggravation of heart failure symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: High Luminance High Contrast Monocular Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Treatment Emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of four-fold or greater serum hemagglutination inhibition (HAI) and/or neutralization antibody rises
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: changes in bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose modification feasibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Control Rate at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of digital ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: Recovery from Alcohol Use Disorder (AUD)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average activity counts/minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stress Index for Parents of Adolescents
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parenting Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Betanechol AUCt,ss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Betanechol Cmax,ss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death with anticoagulant treatment
Endpoint domain: Mortality/survival
Primary endpoint: Hemorrhagic events with anticoagulant treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of life with anticoagulant treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: serological antibodies against SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adverse clinical symptoms after vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Headache Impact Test-6 (HIT-6) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: cold sore severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with a Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Assessment of itch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RSV-A neutralizing titers expressed as group Geometric Mean Titers (GMTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroresponse rate (SRR) in RSV-A neutralizing titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: RSV-B neutralizing titers expressed as GMT ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroresponse rate (SRR) in RSV-B neutralizing titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lymphatic flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Accuracy of predicting diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early onset adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in suicidal ideation and behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unified Parkinson's Disease Rating Scale part III
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Overall Exposure (AUC) of Delafloxacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Parameters, Vital Signs, and 12-Lead Electrocardiogram (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Change in Columbia Suicide Severity Rating Scale (C-SSRS) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Invasiveness degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Therapy response (observer-rated)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of received esketamine treatments in relation to scheduled ones
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ghrelin-induced changes in dopamine release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ghrelin-induced changes in motivation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes (Ghrelin-induced) in hunger and satiety from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of cerebral blood flow perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Venous thromboembolisms
Endpoint domain: Adverse events/effects
Primary endpoint: Postprandial Glucose Incremental Area under the Curve (iAUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effectiveness of oral tofacitinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in glycemic control from baseline to Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in glycemic control from baseline to Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in body mass index from baseline to Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in body mass index from baseline to Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PrEP Penetration
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: muscular reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Osteopontin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Beck Depression Inventory Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total Number of Follow-up Clinical Assessments Completed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in brain functional network connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Humoral immune response against SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma AUC0-t for Ensartinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma AUC0-∞ for Ensartinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Cmax for Ensartinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of trilateral retinoblastoma
Endpoint domain: Mortality/survival
Primary endpoint: Event-free survival after diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: Child Behavior Checklist (CBCL/6-18)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: The Continuous Performance Test (CPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Child Behavioral Health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Success rate of maintaining pulp vitality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Stigma
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Help-seeking Intentions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: slow waves density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Collection of biological samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Collection of biological samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in urinary leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time spent in high-effort rooms
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Psychosocial health due to communication handicaps
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physiological Stress: Salivary Cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Early child development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: relative risk of infection
Endpoint domain: Adverse events/effects
Primary endpoint: Weight standard deviation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive outcome of standardized tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Socio-communicative outcome of standardized tests
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Sensory outcome of standardized tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of electroencephalografic theta power and looking behavior during development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Optimal breastfeeding practice
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Postoperative survival of patients
Endpoint domain: Mortality/survival
Primary endpoint: Scores of patients' quality of life after surgery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: AUC0-72 of the NRS-A pain intensity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity of neutralizing antibody (GMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and Specificity of urinalysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer assessment of upper extremity (FMA-UE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived Caregiving Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Repeatability of organ specific quantitation of radiotracer uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Scale for the Assessment and Rating of Ataxia score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of subjects with genetic mutations of susceptibility to primary PE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VSIT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lidocaine plasmatic levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CR rate at 12 weeks of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-filter iCa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum iCa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum Ca2+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effluent Ca2+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Infusion rate of antibacterial drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of using PBM
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of using PBM
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: adherence to use the remote monitoring app
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: acute asthma exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peak Concentration (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area under the blood concentration time curve (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Decrease in R/I ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: Mean CGM glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGM TIR (70-180mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGM TBR (<70 and <54 mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severe pre-eclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of patients who accept HIV/HCV testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Regression-rate of severe cervical precancerous lesions (CIN 2 and CIN 3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Civic Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in Pro-Social Involvement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in Attitudes towards Violence and Retaliation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Generalized Anxiety Disorder-7 score (GAD-7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Meta-Cognitions Questionnaire-30 score (MCQ-30, negative meta-cognition sub-scale)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Intolerance of Uncertainty Scale-12 score (IUS-12)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Long-Term Care Case-Mix System Score
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Multi-Dimensional Assessment Instrument
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Safety of TILs/CAR-TILs treatment
Endpoint domain: Adverse events/effects
Primary endpoint: subjective International Knee Documentation Committee (IKDC) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Death from a cardiac cause
Endpoint domain: Mortality/survival
Primary endpoint: change in severity of acne scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of Treatment-emergent adverse event (TEAEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with changes in laboratory parameters from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin edema
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of life index (KDQOL) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of sleep Pittsburgh Sleep Quality Index (PSQI) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Brain wave changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Meditation depth Index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: median nerve ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall Wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sequencing Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Molecular Cohort Assignment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cmax: Maximum Observed Plasma Concentration for Soticlestat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Soticlestat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Soticlestat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Indication for Antipsychotic/Benzodiazepine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline stress and coping at 4 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline chronic stress at 4 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Gamma-synuclein level sensitivity and specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced emergency room visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Reduced hospitalization for congestive heart failure symptoms
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Anti-SARS-CoV-2 Spike immunoglobulin G (IgG) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rescue sedation doses
Endpoint domain: Adverse events/effects
Primary endpoint: ONAPS-PAQ questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 24-hour Mean Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Percent Change From Baseline in Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Feasibility of the MAEva programme
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of the MAEva programme
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nutritional status evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Skeletal muscle fiber characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference in intraocular pressure (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with normal serum potassium level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maintenance of Hgb>100g/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in QOL (quality of Life)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Difference in mean VEP latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes